NCT03904303

Brief Summary

Crossover study comparing Moviprep (for bowel cleansing) with a new gel-based colon cleansing agent before colonoscopy

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
16

participants targeted

Target at below P25 for phase_1

Timeline
Completed

Started Jun 2019

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 29, 2019

Completed
2 months until next milestone

First Posted

Study publicly available on registry

April 5, 2019

Completed
2 months until next milestone

Study Start

First participant enrolled

June 1, 2019

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2019

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2020

Completed
Last Updated

June 6, 2019

Status Verified

June 1, 2019

Enrollment Period

7 months

First QC Date

January 29, 2019

Last Update Submit

June 3, 2019

Conditions

Outcome Measures

Primary Outcomes (2)

  • Boston Bowel preparation scale (BBPscale)

    Visual assessment of the degree of bowel cleansing performed by the endoscopist (blinded). Right colon, colon transversum, and left colon are each judged on a scale from 0-3 with higher scores indicating better cleansing. Range of score between 0-9.

    Performed during the endoscopy procedure

  • Adverse events related to intervention

    Any adverse event related to the intervention observed by investigators or as reported by the participant

    Assessed 4 hours after last intake of cleansing product

Secondary Outcomes (4)

  • Blood pressure

    Measured immediately before the colonoscopy starts, and every 5 minutes during colonoscopy and immediately after the end of the examination

  • Saturation

    Measured immediately before the colonoscopy starts, and every 5 minutes during colonoscopy and immediately after the end of the examination

  • Heart rate

    Measured immediately before the colonoscopy starts, and every 5 minutes during colonoscopy and immediately after the end of the examination

  • Respiration frequency

    Measured immediately before the colonoscopy starts, and every 5 minutes during colonoscopy and immediately after the end of the examination

Study Arms (2)

Geloprep

EXPERIMENTAL

Novel and patented Polyethylene glycol 3350 mixture

Drug: A 06 ad

Moviprep

ACTIVE COMPARATOR

Standard of care Polyethylene glycol 3350 mixture

Drug: A 06 ad

Interventions

Colonic cleansing before colonoscopy and CT colonografi

GeloprepMoviprep

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • \- Healthy

You may not qualify if:

  • Allergy to content of products

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Zuh

Køge, Region of Zealand, 4600, Denmark

Location

Study Officials

  • Ismail Gögenur, Professor MD

    Department of Surgery, Zealand University Hospital

    STUDY CHAIR

Central Study Contacts

Svend Knuhtsen, MD

CONTACT

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
OTHER
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 29, 2019

First Posted

April 5, 2019

Study Start

June 1, 2019

Primary Completion

December 31, 2019

Study Completion

December 31, 2020

Last Updated

June 6, 2019

Record last verified: 2019-06

Locations